Measurement of an analog of insulin-like growth factor-I in blood plasma using a novel enzyme-linked immunosorbent assay.

Long-Arg3-IGF-I (LR3IGF-I) is a synthetic analog of IGF-I that has much lower affinity for IGF-binding proteins than do native IGFs-I and -II. Comparisons of the effects of LR3IGF-I with those of IGFs-I and-II in in vitro and in vivo studies have proved useful in defining the functions of IGF-binding proteins. We have developed a sensitive noncompetitive nonisotopic assay of LR3IGF-I. Mouse IgG 1A7-F5-E5 binds an epitope that contains the substituted arginine3 in LR3IGF-I and was used as the solid phase antibody. The solution phase antibody was a rabbit immunoglobulin Nelson which binds to an epitope that is common to IGF-I and LR3IGF-I. The ELISA system was able to detect as little as 50 pg LR3IGF-I in 100 microliters and the native peptides IGFs-I and -II have less than 0.01% activity. Blood plasma from animals treated with pharmacologically active doses of this growth factor analog could be diluted 33.3-fold before assay, at which concentrations plasma had no significant effect on the assay. The ELISA response to LR3IGF-I was unaffected by the presence of IGF-binding proteins. The intra-assay and interassay coefficients of variation are 2.8 and 7.3% respectively. Recovery of LR3IGF-I added to blood plasma was approximately 90%. The ELISA was used to measure LR3IGF-I concentrations in plasma of cows treated with a pharmacologically active dose of this peptide and the results were compared with those obtained by a previously established LR3IGF-I RIA that requires size exclusion chromatography of plasma under acidic conditions to eliminate IGF-binding protein artefacts from the RIA. There was a positive correlation between results obtained by the two assays. The LR3IGF-I ELISA permits discrimination between the exogenous synthetic IGF-I analog and the endogenous native IGFs-I and -II in animals treated with this growth factor without the need for radioiodination of LR3IGF-I and elimination of the requirement for extraction of plasma before assay.

[1]  S. E. Knowles,et al.  Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects. , 1993, The Biochemical journal.

[2]  R. Baxter,et al.  Comparison of extraction methods for insulin-like growth factor-I in rat serum. , 1992, The Journal of endocrinology.

[3]  J. Wallace,et al.  Circulating levels of insulin-like growth factors increase and molecular forms of their serum binding proteins change with human pregnancy. , 1990, Biochemical and biophysical research communications.

[4]  W. Daughaday,et al.  Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay. , 1987, The Journal of laboratory and clinical medicine.

[5]  F. Liu,et al.  Demonstration of specific plasma protein binding sites for somatomedin. , 1977, The Journal of clinical endocrinology and metabolism.

[6]  J. Wallace,et al.  Sheep insulin-like growth factors I and II: sequences, activities and assays. , 1989, Endocrinology.

[7]  P. Gluckman,et al.  Radioimmunoassay for insulin-like growth factor-I: solutions to some potential problems and pitfalls. , 1991, The Journal of endocrinology.

[8]  J. Wallace,et al.  Isolation and characterization of ovine IGFBP-4: protein purification and cDNA sequence. , 1994, Journal of molecular endocrinology.

[9]  R. J. Johnson,et al.  Growth hormone increases insulin-like growth factor-I (IGF-I) and decreases IGF-II in plasma of growing pigs. , 1990, The Journal of endocrinology.

[10]  M. Rechler.  Insulin-like growth factor binding proteins. , 1993, Vitamins and hormones.

[11]  J. Wallace,et al.  Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency. , 1992, Journal of molecular endocrinology.

[12]  R. Baxter,et al.  Insulin-like growth factor (IGF) binding protein-3 in pregnancy serum binds native IGF-I but not iodo-IGF-I. , 1991, The Journal of clinical endocrinology and metabolism.

[13]  G. Scatchard,et al.  THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .

[14]  D. Powell,et al.  Serum somatomedin levels in adults with chronic renal failure: the importance of measuring insulin-like growth factor I (IGF-I) and IGF-II in acid-chromatographed uremic serum. , 1986, The Journal of clinical endocrinology and metabolism.

[15]  J. Wallace,et al.  Circulating insulin-like growth factors (IGFs), IGF-binding proteins (IGFBPs) and tissue mRNA levels of IGFBP-2 and IGFBP-4 in the ovine fetus. , 1995, The Journal of endocrinology.

[16]  S. E. Knowles,et al.  Anabolic effects of insulin-like growth factor-I (IGF-I) and an IGF-I variant in normal female rats. , 1993, The Journal of endocrinology.

[17]  J. Mistry,et al.  Noncompetitive ELISA for human serum insulin-like growth factor-I. , 1996, Clinical chemistry.

[18]  S. E. Knowles,et al.  Insulin-like growth factor-I (IGF-I) and especially IGF-I variants are anabolic in dexamethasone-treated rats. , 1992, The Biochemical journal.